Prevalence and Incidence of Depression during Interferon-Based Antiviral Therapy in Chronic Hepatitis C Patients in the Republic of Korea
1
조회
0
다운로드
0
인용
0
참고문헌
키워드
초록
Background/Aims: The association between depression and chronic hepatitis C virus (HCV) infection or pegylated interferon α and ribavirin therapy (PR therapy) has not been extensively studied in Korea. We aimed to clarify the prevalence of depression and its incidence during PR therapy in chronic hepatitis C (CHC) patients. Methods: In this prospective, multicenter study, 114 CHC patients were screened for depression using two self-reported scales, the Beck Depression Inventory-I (BDI-I) and the Hospital Anxiety and Depression scale (HADS). The incidence of depression during PR therapy was evaluated in 62 patients who underwent PR therapy during the study period. Results: The prevalence of baseline depression was 17.5% according to the BDI-I score ≥10 criterion and 4.4% according to the HADS-D score ≥8 criterion in the 114 CHC patients, and it was significantly associated with an unmarried state. During PR therapy, depression developed in 34.6% according to the BDI-I scale and 29.5% according to the HADS-D, which negatively affected sustained virologic response (SVR). Conclusions: The prevalence of depression in Korean CHC patients appears to be low compared to that in Western patients; however, its incidence during PR therapy (approximately 30%) was similar to that of other populations, which led to a lower SVR rate. Active screening and multidisciplinary management of depression during PR therapy is warranted.
Abstract
Background/Aims: The association between depression and chronic hepatitis C virus (HCV) infection or pegylated interferon α and ribavirin therapy (PR therapy) has not been extensively studied in Korea. We aimed to clarify the prevalence of depression and its incidence during PR therapy in chronic hepatitis C (CHC) patients. Methods: In this prospective, multicenter study, 114 CHC patients were screened for depression using two self-reported scales, the Beck Depression Inventory-I (BDI-I) and the Hospital Anxiety and Depression scale (HADS). The incidence of depression during PR therapy was evaluated in 62 patients who underwent PR therapy during the study period. Results: The prevalence of baseline depression was 17.5% according to the BDI-I score ≥10 criterion and 4.4% according to the HADS-D score ≥8 criterion in the 114 CHC patients, and it was significantly associated with an unmarried state. During PR therapy, depression developed in 34.6% according to the BDI-I scale and 29.5% according to the HADS-D, which negatively affected sustained virologic response (SVR). Conclusions: The prevalence of depression in Korean CHC patients appears to be low compared to that in Western patients; however, its incidence during PR therapy (approximately 30%) was similar to that of other populations, which led to a lower SVR rate. Active screening and multidisciplinary management of depression during PR therapy is warranted.
참고문헌 (29)
- Adinolfi LE, "Chronic hepatitis C virus infection and neurological and psychiatric disorders: an overview", World J Gastroenterol, 21, pp.2269~2280 (2015)
- Conversano C, "Interferon alpha therapy in patients with chronic hepatitis C infection: quality of life and depression", Hematol Rep, 7, pp.5632~ (2015)
- Asnis GM, "Interferon-induced depression in chronic hepatitis C: a review of its prevalence, risk factors, biology, and treatment approaches", J Clin Gastroenterol, 40, pp.322~335 (2006)
- Huckans M, "A longitudinal study evaluating the effects of interferon-alpha therapy on cognitive and psychiatric function in adults with chronic hepatitis C", J Psychosom Res, 78, pp.184~192 (2015)
- Chapman J, "Changes in depressive symptoms and impact on treatment course among hepatitis C patients undergoing interferon-α and ribavirin therapy: a prospective evaluation", Am J Gastroenterol, 106, pp.2123~2132 (2011)
- Stewart B, "Anxiety and depression in Australian chronic hepatitis C outpatients: prevalence and predictors", Australas Psychiatry, 20, pp.496~500 (2012)
- Boscarino JA, "Predictors of poor mental and physical health status among patients with chronic hepatitis C infection: the Chronic Hepatitis Cohort Study (CHeCS)", Hepatology, 61, pp.802~811 (2015)
- Seong MH, "Clinical and epidemiological features of hepatitis C virus infection in South Korea: a prospective, multicenter cohort study", J Med Virol, 85, pp.1724~1733 (2013)
- 김종엽, "Behavioral and Healthcare-Associated Risk Factors for Chronic Hepatitis C Virus Infection in Korea", Journal of Korean Medical Science, 27(11), pp.1371~1377 (2012), 대한의학회
- Beck AT, "An inventory for measuring depression", Arch Gen Psychiatry, 4, pp.561~571 (1961)
- Holtzheimer PE, "Utility of the Beck Depression Inventory to screen for and track depression in injection drug users seeking hepatitis C treatment", Gen Hosp Psychiatry, 32, pp.426~432 (2010)
- Shin MS, "The cut-off score for the Korean version of Beck Depression Inventory", Korean J Clin Psychol, 12, pp.71~81 (1993)
- Bjelland I, "The validity of the Hospital Anxiety and Depression scale: an updated literature review", J Psychosom Res, 52, pp.69~77 (2002)
- Weinstein AA, "Depression in patients with nonalcoholic fatty liver disease and chronic viral hepatitis B and C", Psychosomatics, 52, pp.127~132 (2011)
- Evon DM, "Prospective analysis of depression during peginterferon and ribavirin therapy of chronic hepatitis C: results of the Virahep-C study", Am J Gastroenterol, 104, pp.2949~2958 (2009)
- Fireman M, "Addressing tri-morbidity (hepatitis C, psychiatric disorders, and substance use): the importance of routine mental health screening as a component of a comanagement model of care", Clin Infect Dis, 40(Suppl 5), pp.S286~S291 (2005)
- el-Serag HB, "Psychiatric disorders among veterans with hepatitis C infection", Gastroenterology, 123, pp.476~482 (2002)
- Lee K, "Association of chronic liver disease with depression: a populationbased study", Psychosomatics, 54, pp.52~59 (2013)
- Wang Z, "Hepatitis C virus infection is independently associated with depression among methadone maintenance treatment heroin users in China", Asia Pac Psychiatry, 5, pp.191~196 (2013)
- Nomura H, "Occurrence of clinical depression during combination therapy with pegylated interferon alpha or natural human interferon beta plus ribavirin", Hepatol Res, 42, pp.241~247 (2012)
- Mangia A, "A randomized controlled trial of pegylated interferon alpha-2a (40 KD) or interferon alpha-2a plus ribavirin and amantadine vs interferon alpha-2a and ribavirin in treatment-naïve patients with chronic hepatitis C", J Viral Hepat, 12, pp.292~299 (2005)
- Bonaccorso S, "Depression induced by treatment with interferon-alpha in patients affected by hepatitis C virus", J Affect Disord, 72, pp.237~241 (2002)
- Miyaoka H, "Depression from interferon therapy in patients with hepatitis C", Am J Psychiatry, 156, pp.1120~ (1999)
- Mahajan S, "Role of baseline depressive symptoms in the development of depressive episode in patients receiving antiviral therapy for hepatitis C infection", J Psychosom Res, 77, pp.109~115 (2014)
- Medeiros LP, "Interferon- induced depression in patients with hepatitis C: an epidemiologic study", Rev Assoc Med Bras, 60, pp.35~39 (2014)
- Armstrong GL, "The prevalence of hepatitis C virus infection in the United States, 1999 through 2002", Ann Intern Med, 144, pp.705~714 (2006)
- Raison CL, "Depression during pegylated interferon-alpha plus ribavirin therapy: prevalence and prediction", J Clin Psychiatry, 66, pp.41~48 (2005)
- Liu SS, "Impact of depressive symptoms and their treatment on completing antiviral treatment in patients with chronic hepatitis C", J Clin Gastroenterol, 44, pp.e178~e185 (2010)
- Patterson AL, "Screening for depression in patients with hepatitis C using the Beck Depression Inventory-II: do somatic symptoms compromise validity?", Gen Hosp Psychiatry, 33, pp.354~362 (2011)